Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Operating Officer

Chief Financial Officer

President & CEO

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRÃƒÅ¸), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRÃƒÅ¸ for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and end...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-03-27	Premium	acquired	Premium	Premium	Premium	Chief Operating Officer
2024-03-27	Premium	sold (taxes)	Premium	Premium	Premium	Chief Financial Officer
2024-03-27	Premium	sold (taxes)	Premium	Premium	Premium	Chief Operating Officer
2024-03-27	Premium	acquired	Premium	Premium	Premium	President & CEO
2024-03-27	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-03-27	Premium	sold (taxes)	Premium	Premium	Premium	President & CEO
2024-03-01	Premium	sold (taxes)	Premium	Premium	Premium	President & CEO
2024-03-01	Premium	sold (taxes)	Premium	Premium	Premium	Chief Financial Officer
2024-03-01	Premium	acquired	Premium	Premium	Premium	President & CEO
2024-03-01	Premium	sold (taxes)	Premium	Premium	Premium	Chief Operating Officer
2024-03-01	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-03-01	Premium	acquired	Premium	Premium	Premium	Chief Operating Officer
2024-02-09	Premium	sold	Premium	Premium	Premium	President & CEO
2024-02-08	Premium	acquired	Premium	Premium	Premium	President & CEO
2024-02-08	Premium	acquired	Premium	Premium	Premium	-
2024-02-08	Premium	sold	Premium	Premium	Premium	-
2024-02-08	Premium	sold	Premium	Premium	Premium	President & CEO
2024-01-31	Premium	acquired	Premium	Premium	Premium	President & CEO
2024-01-31	Premium	sold	Premium	Premium	Premium	President & CEO
2024-01-30	Premium	sold	Premium	Premium	Premium	President & CEO
2024-01-30	Premium	acquired	Premium	Premium	Premium	President & CEO
2024-01-19	Premium	sold	Premium	Premium	Premium	-
2024-01-19	Premium	acquired	Premium	Premium	Premium	-
2024-01-04	Premium	sold (taxes)	Premium	Premium	Premium	President & CEO
2024-01-04	Premium	sold	Premium	Premium	Premium	Chief Financial Officer

VKTX - Viking Therapeutics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for VKTX